期刊
JOURNAL OF PHARMACOLOGICAL SCIENCES
卷 140, 期 1, 页码 109-112出版社
JAPANESE PHARMACOLOGICAL SOC
DOI: 10.1016/j.jphs.2019.04.005
关键词
Cancer cachexia; Metabolome; Xanthine oxidase
资金
- Japan Society for the Promotion of Sciences (JSPS) KAKENHI [JP201604170, JP18K15037, JP16K21645, JP16K08568]
Cancer cachexia is a systemic wasting syndrome characterized by anorexia and loss of body weight. The xanthine oxidase (XO) inhibitor febuxostat is one of the promising candidates for cancer cachexia treatment. However, cachexic symptoms were not alleviated by oral administration of febuxostat in our cancer cachexia model. Metabolomic analysis with brains of our cachexic model showed that purine metabolism was activated and XO activity was increased, and thus suggested that febuxostat would not reach the brain. Accordingly, targeting XO in the brain, which controls appetite, may be an effective strategy for treatment of cancer cachexia. (C) 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据